Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Allergy and Clinical Immunology

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jaci.2014.01.002PMID 24582316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody biodistribution coefficients

  2013cited by this paper
• Th17-mediated inflammation in asthma.

  2013cited by this paper
• Dupilumab in persistent asthma with elevated eosinophil levels.

  2013cited by this paper
• A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics.

  2013cited by this paper
• A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

  2012cited by this paper
• Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

  2012cited by this paper
• Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production.

  2011cited by this paper
• Lebrikizumab treatment in adults with asthma.

  2011cited by this paper
• IL-13 Antibodies Influence IL-13 Clearance in Humans by Modulating Scavenger Activity of IL-13Rα2

  2011cited by this paper
• Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Ralpha2.

  2010cited by this paper
• Subclinical phenotypes of asthma

  2010cited by this paper
• Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

  2010cited by this paper
• Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease

  2010cited by this paper
• A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma.

  2010cited by this paper
• Effect of interleukin 13 on bronchial hyperresponsiveness and the bronchoprotective effect of beta-adrenergic bronchodilators and corticosteroids.

  2009cited by this paper
• T-helper type 2-driven inflammation defines major subphenotypes of asthma.

  2009cited by this paper
• Keratinocytes treated with peptidoglycan from Staphylococcus aureus produce vascular endothelial growth factor, and its expression is amplified by the subsequent production of interleukin‐13

  2009cited by this paper
• The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance.

  2009cited by this paper
• Increased sputum and bronchial biopsy IL-13 expression in severe asthma.

  2008cited by this paper
• Secretion of IL-13 by airway epithelial cells enhances epithelial repair via HB-EGF.

  2008cited by this paper
• Extent of uncontrolled disease and associated medical costs in severe asthma – a PHARMO study*

  2008cited by this paper
• Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system.

  2008cited by this paper
• Cluster analysis and clinical asthma phenotypes.

  2008cited by this paper
• Extent, patterns, and burden of uncontrolled disease in severe or difficult‐to‐treat asthma

  2007cited by this paper
• The reclassification of asthma based on subphenotypes

  2007cited by this paper
• Persistent effects induced by IL-13 in the lung.

  2006cited by this paper
• IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis.

  2006cited by this paper
• IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis

  2006cited by this paper
• Standardisation of spirometry

  2005cited by this paper
• Interleukin‐13 in asthma pathogenesis

  2004cited by this paper
• Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.

  2004cited by this paper
• Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling.

  2004cited by this paper
• IL-13 receptors and signaling pathways: an evolving web.

  2003cited by this paper
• Pathology of difficult asthma.

  2003cited by this paper
• IL-4, IL-13, and dexamethasone augment fibroblast proliferation in asthma.

  2001cited by this paper
• Measuring asthma control. Clinic questionnaire or daily diary?

  2000cited by this paper
• Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma

  1999cited by this paper
• Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.

  1999cited by this paper
• Development and validation of a questionnaire to measure asthma control.

  1999cited by this paper
• Interleukin-13: central mediator of allergic asthma

  1998cited by this paper
• Interleukin-13: central mediator of allergic asthma.

  1998cited by this paper
• A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity.

  1996cited by this paper
• The B-value: a tool for monitoring data.

  1988cited by this paper
• Standardization of spirometry.

  1987cited by this paper

• Application of Biologics in the Treatment of Asthma in the Past Two Decades: A Bibliometric Analysis and Beyond

  2025cites this paper
• Eosinophil-derived interleukin-24 compromises epithelial integrity and aggravates airway remodeling in mouse models of allergic asthma

  2025cites this paper
• A review of the pathophysiology and the role of ion channels on bronchial asthma

  2023cites this paper
• Aiming to IgE: Drug development in allergic diseases.

  2023cites this paper
• A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults

  2023cites this paper
• The effect of an Iranian polyherbal formulation on the management of allergic asthma in mice

  2023cites this paper
• The ins and outs of innate and adaptive type 2 immunity.

  2023cites this paper
• The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis

  2023cites this paper
• Investigational anti IL-13 asthma treatments: a 2023 update

  2023influential citation
• Editorial: The importance of Th17/Treg imbalance in asthma and COPD development and progression

  2022cites this paper
• Anti-IL-5 therapies for asthma.

  2022cites this paper
• Current options and investigational drugs for the treatment of eosinophilic esophagitis

  2022cites this paper
• Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives

  2022cites this paper
• Biologics in Asthma: A Molecular Perspective to Precision Medicine

  2022cites this paper
• Immunological background for treatments with biologicals in CRSwNP

  2021cites this paper
• MicroRNA Targets for Asthma Therapy.

  2021cites this paper
• Asthma: Pathophysiology, Herbal and Modern Therapeutic Interventions

  2021cites this paper
• IL-13 Augments Histone Demethylase JMJD2B/KDM4B Expression Levels, Activity, and Nuclear Translocation in Airway Fibroblasts in Asthma

  2021cites this paper
• Modulating Th2 Cell Immunity for the Treatment of Asthma

  2021cites this paper
• Tacrolimus (FK506) treatment protects allergen‐, IL‐5‐ and IL‐13‐induced mucosal eosinophilia

  2021cites this paper
• Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.

  2021cites this paper
• A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs

  2021cites this paper
• Cytokine-Based Therapies

  2021cites this paper
• Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors

  2021cites this paper
• Bronchial Vascular Remodeling Is Attenuated by Anti-IL-17 in Asthmatic Responses Exacerbated by LPS

  2020cites this paper
• Anti-IL-4/IL-13 for the treatment of asthma: the story so far

  2020cites this paper
• Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.

  2020cites this paper
• The Cytokines of Asthma.

  2019cites this paper
• Novel Biological Therapies in Severe Asthma: Targeting the Right Trait.

  2019cites this paper
• Inadequate assessment of adherence to maintenance medication leads to loss of power and increased costs in trials of severe asthma therapy: results from a systematic literature review and modelling study

  2019cites this paper
• Regulation of IL-17A and implications for TGF-β1 comodulation of airway smooth muscle remodeling in severe asthma.

  2019cites this paper
• Randomized clinical trials with run-in periods: frequency, characteristics and reporting

  2019cites this paper
• Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

  2019cites this paper
• The role of mast cells, T cells and their cytokines in Allergic Conjunctivitis

  2019cites this paper
• Role of IL-17 in asthma pathogenesis and its implications for the clinic

  2019cites this paper
• The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets

  2019cites this paper
• Severe Asthma

  2019cites this paper
• Opening the Window of Immune Opportunity: Treating Childhood Asthma.

  2019cites this paper
• Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis

  2019cites this paper
• Dendritic Cell-Mediated Th2 Immunity and Immune Disorders

  2019cites this paper
• Pharmacologic Therapies for Severe Asthma

  2018cites this paper
• A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma

  2018cites this paper
• Inhaled Antisense for Treatment of Respiratory Disease

  2018cites this paper
• Human lung tissue provides highly relevant data about efficacy of new anti-asthmatic drugs

  2018cites this paper
• Immunologie der Polyposis nasi als Grundlage für eine Therapie mit Biologicals

  2018cites this paper
• Immune Dysregulation in Children with Allergic Asthma: A Close Relationship Between IL-17 but not IL-4 or IFN-

  2018cites this paper
• Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond

  2018cites this paper
• Targeted anti-IL-13 therapies in asthma: current data and future perspectives

  2018cites this paper
• Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review

  2018cites this paper
• Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for “Omics” Technology?

  2018cites this paper
• Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment

  2018cites this paper
• Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies.

  2018cites this paper
• Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942

  2018cites this paper
• Tricellulin is regulated via interleukin 13 receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis

  2017cites this paper
• Association between IL-13 +1923C/T polymorphism and asthma risk: a meta-analysis based on 26 case-control studies

  2017cites this paper
• Dupilumab for the treatment of asthma

  2017cites this paper
• Targeted Therapy for Severe Asthma: Identifying the Right Patients

  2017cites this paper
• Patient stratification and the unmet need in asthma.

  2017cites this paper
• Novel monoclonal treatments in severe asthma

  2017cites this paper
• Anti-IL5 therapies for asthma.

  2017cites this paper
• Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations

  2017cites this paper
• New perspectives on the regulation of type II inflammation in asthma

  2017cites this paper
• Dupilumab in the management of moderate-to-severe asthma: the data so far

  2017cites this paper
• Innate lymphoid cells: the role in respiratory infections and lung tissue damage

  2017cites this paper
• Current and future management of the young child with early onset wheezing

  2017cites this paper
• Targeting cytokines in asthma therapy: could IL-37 be a solution?

  2017cites this paper
• Pulmonary Susceptibility of Neonates to Respiratory Syncytial Virus Infection: A Problem of Innate Immunity?

  2017cites this paper
• Anticytokine therapy of allergic asthma

  2017cites this paper
• Tomatidine Attenuates Airway Hyperresponsiveness and Inflammation by Suppressing Th2 Cytokines in a Mouse Model of Asthma

  2017cites this paper
• Eosinophil Cytokines in Allergy

  2017cites this paper
• Anti-interleukin-13, a Monoclonal Antibody, in Uncontrolled Asthma: Systematic Review and Meta-analysis

  2017cites this paper
• Anti-IL-4/IL-13 Biologics

  2017cites this paper
• Specific Therapies for Asthma Endotypes: A New Twist in Drug Development

  2017cites this paper
• The Role of Cytokines in the Pathogenesis of Bronchial Asthma and the Possibilities of Anti-Cytokine Therapy

  2017cites this paper
• Th17 regulating lower airway disease

  2016cites this paper
• Asthma and Atopic Dermatitis: A Review of Targeted Inhibition of Interleukin-4 and Interleukin-13 As Therapy for Atopic Disease.

  2016cites this paper
• Asthma bronchiale bei Erwachsenen

  2016cites this paper
• Anti-Inflammatory Treatment of Asthma

  2016cites this paper
• Targeting Single Molecules in Asthma Benefits Few.

  2016cites this paper
• Do insights from mice imply that combined Th2 and Th17 therapies would benefit select severe asthma patients?

  2016cites this paper
• Translational studies of viral-induced asthma and COPD exacerbations

  2016cites this paper
• Sputum mediator profiling in severe asthma: relationships with clinical phenotypes, airway inflammation and morphometry in stable disease and at exacerbations

  2016cites this paper
• 37 – Refractory Childhood Asthma: Assessment and Management

  2016cites this paper
• The Use of Adjuvants for Enhancing Allergen Immunotherapy Efficacy.

  2016cites this paper
• The Efficacy and Safety of Antiinterleukin 13, a Monoclonal Antibody, in Adult Patients With Asthma

  2016cites this paper
• Modulating steroid insensitive pathways in airway smooth muscle cells

  2016cites this paper
• Biomarkers in the clinical development of asthma therapies.

  2016cites this paper
• Future treatment for asthma

  2016cites this paper
• Emerging Biologics in Severe Asthma.

  2016cites this paper
• Biomarkers and asthma management: an update

  2016influential citation
• Serum IL‐5 and IL‐13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics

  2016cites this paper
• Current and future biomarkers in allergic asthma

  2016cites this paper
• Molecular Mechanisms of Airway Hyperresponsiveness in a Murine Model of Steroid-Resistant Airway Inflammation

  2016cites this paper
• Where does current and future pediatric asthma treatment stand? Remodeling and inflammation: Bird's eye view

  2016cites this paper
• Biomarkers in the Management of Difficult Asthma

  2016cites this paper
• Biological Modulators in Eosinophilic Diseases

  2016cites this paper
• Targeting the JAK-STAT pathway in the treatment of 'Th2-high' severe asthma.

  2016cites this paper
• Development of New Therapies for Severe Asthma

  2016cites this paper
• Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.

  2016cites this paper
• Targeting the IL-33/IL-13 Axis for Respiratory Viral Infections.

  2016cites this paper